(3.236.138.35)
Users online: 2517    [ij] [ij] [ij] 
Email id
 

Research Journal of Pharmacy and Technology
Year : 2016, Volume : 9, Issue : 6
First page : ( 694) Last page : ( 698)
Print ISSN : 0974-3618. Online ISSN : 0974-360X.
Article DOI : 10.5958/0974-360X.2016.00130.X

Clinical Comparison of Serum Lipids between Cyclosporine and Tacrolimus Treated Renal Transplant Recipients

Sarumathy S.*, George P. Samuel Gideon, Kumar B. Yeswanth Prasanna, Mukundan V. Atheena, Shanmugarajan T.S., Maheshwari P.

Department of Pharmacy Practice, School of Pharmaceutical Sciences, Vels University (VISTAS), Pallavaram, Chennai-600117, Tamilnadu, India

*Corresponding Author E-mail: saruprabakar@gmail.com

Online published on 21 July, 2016.

Abstract

Introduction

Dyslipidemia is a common complication of renal transplantation referred to as new onset dyslipidemia. Immune suppressants, in particular cyclosporine, the calcineurin inhibitor and others are known to cause dyslipidemia through non-competitive inhibition of sterol 27-dehydroxylase (CYP27A1). On the other hand, dyslipidemia has been found to be associated with higher graft rejection due to decrease in immune suppressant activity and direct graft destruction. Hence the study was designed to analyze the effect of dyslipidemia on chronic allograft rejection.

Methods

This retrospective observational study was carried out in the nephrology department of a multispecialty hospital for a period of two months. Clinical and biochemistry reports of 142 renal transplant recipients were collected in designed case report forms. All statistical analysis was carried out using IBM SPSS Statistics 17 and Graph pad Prism 6.0.

Results

Higher serum lipid levels are observed in patients with cyclosporine therapy than tacrolimus. However statistical significant difference only in levels of total cholesterol, LDL-C, triglycerides was observed between cyclosporine and tacrolimus treated patients (P<0.001).

Conclusion

Dyslipidemic potential of tacrolimus is comparatively lesser than cyclosporine. However, tacrolimus causes dyslipidemia to a lesser when compared to cyclosporine. Thus monoclonal antibodies such as rituximab or basiliximab should be preferred over conventional immune suppressants. However, the cost effectiveness of monoclonal antibody therapy is high. Hence we conclude that tacrolimus with dose intense therapy should be preferred as first line immunosuppressant regimen.

Top

Keywords

Renal transplant, Immunosuppressant, Metabolic Syndrome, Dyslipidemia, Graft Rejection.

Top

  
║ Site map ║ Privacy Policy ║ Copyright ║ Terms & Conditions ║ Page Rank Tool
612,866,804 visitor(s) since 30th May, 2005.
All rights reserved. Site designed and maintained by DIVA ENTERPRISES PVT. LTD..
Note: Please use Internet Explorer (6.0 or above). Some functionalities may not work in other browsers.